Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus
A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
1 . A compound of Formula (I) or (II):
or a pharmaceutically acceptable salt or ester thereof, wherein:
R 1 is independently H, optionally substituted alkyl; acyl; phosphate; sulfonate ester including optionally substituted alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate;
each A is independently a straight, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, CO—O-alkoxyalkyl, CONHR 4 , C(NR 4 )N(R 4 ) 2 , C(S)N(R 4 ) 2 , CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N 3 , OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, —O-aralkyl, —O-acyl, —O-cycloalkyl, —NH-alkyl, —N-dialkyl, —NH-acyl, —NH-aryl, —NH-aralkyl, —NH-cycloalkyl, SH, —S-alkyl, —S-acyl, —S-aryl, —S-cycloalkyl, —S-aralkyl, —CO 2 -alkyl, —CONH-alkyl, —CON-dialkyl, CF 3 , —CH m OH, —(CH 2 ) m NH 2 , —(CH 2 ) m C(O)OH, —(CH 2 ) m CN, —(CH 2 ) m NO 2 , —(CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy;
each B is independently H, a straight chained, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, —CO—O-alkoxyalkyl, —CONHR 4 , —C(NR 4 )N(R 4 ) 2 , —C(S)N(R 4 ) 2 , —CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N 3 , OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, —O-aralkyl, —O-acyl, —O-cycloalkyl, —NH-alkyl, —N-dialkyl, —NH-acyl, —NH-aryl, —NH-aralkyl, —NH-cycloalkyl, SH, —S-alkyl, —S-acyl, —S-aryl, —S-cycloalkyl, —S-aralkyl, —CO 2 -alkyl, —CONH-alkyl, —CON-dialkyl, CF 3 , —CH m OH, —(CH 2 ) m NH 2 , —(CH 2 ) m C(O)OH, —(CH 2 ) m CN, —(CH 2 ) m NO 2 , —(CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy;
each Y 3 is independently H, F, Cl, Br or I;
each R 4 and R 5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl.
X is O or CH;
each R 6 is independently an optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, —(CH 2 ) m C(O)OR 4 , —(CH 2 ) m C(O)NHR 4 , —(CH 2 ) m C(O)N(R 4 ) 2 , C(O)OR 4 or cyano;
each R 7 is independently OH, OR 2 , optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted heteroaryl, —(CH 2 ) m C(O)OR 4 , (CH 2 ) m C(6)SR 4 —(CH 2 ) m C(O)NHR 4 , —(CH 2 ) n C(O)N(R 4 ) 2 , —C(O)OR 4 , —C(O)SR 4 , —O(R 4 ), S(R 4 ), NO 2 , —NR 4 R 5 , azido, cyano, SCN, OCN, NCO or halo;
each R 8 and R 11 is independently hydrogen, an optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, alkenyl, alkynyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, —CH 2 C(O)N(R 4 ) 2 , —(CH 2 ) m C(O)OR 1 , —(CH 2 ) m C(O)NHR 4 , —C(O)OR 4 , cyano, NH-acyl or N(acyl) 2 ;
each R 9 and R 10 are independently hydrogen, OH, OR 2 , optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, alkenyl, alkynyl, NO 2 , haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted heteroaryl, —(CH 2 ) m C(O)OR 4 —(CH 2 ) m C(O)SR 4 , —(CH 2 ) m C(O)NHR 4 , —(CH 2 ) m C(O)N(R 4 ) 2 , —C(O)OR 4 , —C(O)SR 4 , —O(R 4 ), —O(aralkyl), —S(R 4 ), NO 2 , —NR 4 R 5 , —NH(aralkyl), azido, cyano, SCN, OCN, NCO or halo;
each m is independently 1 or 2; and
alternatively, R 6 and R 10 , R 7 and R 9 , R 8 and R 7 or R 9 and R 11 can come together to form a bridged compound selected from the group consisting of optionally substituted carbocycle or optionally substituted heterocycle; or
alternatively, R 6 and R 7 or R 9 and R 10 can come together to form a spiro compound selected from the group consisting of optionally substituted carbocycle or optionally substituted heterocycle; and
each W is independently O, S or CH.
2 . The compound of claim 1 wherein the compound is of Formula I.
3 . The compound of claim 1 wherein W is O.
4 . The compound of claim 1 wherein each B is independently H or a straight chained, branched or cyclic optionally substituted alkyl.
5 . The compound of claim 3 wherein each B is H.
6 . The compound of claim 1 wherein R 7 and R 9 are independently OH or OR 2 .
7 . The compound of claim 1 wherein R 1 is H or phosphate.
8 . The compound of claim 1 wherein A is CONHR 4 .
9 . A compound of Formula (III), (IV) or (V),
or a pharmaceutically acceptable salt or ester thereof, wherein:
R 1 , R 2 and R 3 are each independently H, optionally substituted alkyl; acyl; phosphate; sulfonate ester including optionally substituted alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 , R 2 or R 3 is independently H or phosphate; wherein in one embodiment R 2 and/or R 3 is not phosphate;
each R 6 is independently H, OH, NO 2 , halo, azido, alkenyl and alkynyl an optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, —(CH 2 ) m C(O)OR 4 , —(CH 2 ) m C(O)NHR 4 , —(CH 2 ) m C(O)N(R 4 ) 2 , C(O)OR 4 or cyano;
X and X* are independently O or CH;
each R 7 is independently OH, OR 2 , optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted heteroaryl, —(CH 2 ) m C(O)OR 4 , (CH 2 ) m C(O)SR 4 —(CH 2 ) m C(O)NHR 4 , (CH 2 ) m C(O)N(4) 2 , —C(O)OR 4 , —C(O)SR 4 , —O(R 4 ), —S(4), NO 2 , —NR 4 R 5 , azido, cyano, SCN, OCN, NCO or halo; and
alternatively, R 6 and R 7 can come together to form a spiro compound selected from the group consisting of optionally substituted carbocycle or optionally substituted heterocycle;
each m is independently 1 or 2;
and Base is independently:
wherein
each A is independently a straight, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, CO—O-alkoxyalkyl, CONHR 4 , C(NR 4 )N(R 4 ) 2 , C(S)N(R 4 ) 2 , CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N 3 , OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, —O-aralkyl, —O-acyl, —O-cycloalkyl, —NH-alkyl, —N-dialkyl, —NH-acyl, —NH-aryl, —NH-aralkyl, —NH-cycloalkyl, SH, —S-alkyl, —S-acyl, —S-aryl, —S-cycloalkyl, —S-aralkyl, —CO 2 -alkyl, —CONH-alkyl, —CON-dialkyl, CF 3 , —CH m OH, —(CH 2 ) m NH 2 , —(CH 2 ) m C(O)OH, —(CH 2 ) m CN, —(CH 2 ) m NO 2 , —(CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy;
each B is independently H, a straight chained, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, —CO—O-alkoxyalkyl, —CONHR 4 , —C(NR 4 )N(R 4 ) 2 , —C(S)N(R 4 ) 2 , —CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N 3 , OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, —O-aralkyl, —O-acyl, —O-cycloalkyl, —NH-alkyl, —N-dialkyl, —NH-acyl, —NH-aryl, —NH-aralkyl, —NH-cycloalkyl, SH, —S-alkyl, —S-acyl, —S-aryl, —S-cycloalkyl, —S-aralkyl, —CO 2 -alkyl, —CONH-alkyl, —CON-dialkyl, CF 3 , —CH m OH, —(CH 2 ) m NH 2 , —(CH 2 ) m C(O)OH, —(CH 2 ) m CN, —(CH 2 ) m NO 2 , —(CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy; and
each W is independently O, S or CH.
10 . A compound of Formula (VI),
or a pharmaceutically acceptable salt or ester thereof, wherein:
R 1 is independently H, optionally substituted alkyl; acyl; phosphate; sulfonate ester including optionally substituted alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate;
each A is independently a straight chained, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, CO—O-alkoxyalkyl, CONHR 4 , C(NR 4 )N(R 4 ) 2 , C(S)N(R 4 ) 2 , CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N3, OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, O-alkenyl, O-alkynyl, O-aryl, O-aralkyl, —O-acyl, O-cycloalkyl, NH-alkyl, N-dialkyl, NH-acyl, N-aryl, N-aralkyl, NH-cycloalkyl, SH, S-alkyl, S-acyl, S-aryl, S-cycloalkyl, S-aralkyl, CO 2 -alkyl, CONH-alkyl, CON-dialkyl, CF 3 , CH m OH, (CH 2 ) m NH 2 , (CH 2- ) m C(O)OH, (CH 2 ) m CN, (CH 2 ) m NO 2 (CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy;
each B is independently H, a straight chained, branched or cyclic optionally substituted alkyl, CH 3 , CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , CH 2 OH, optionally substituted alkenyl, optionally substituted alkynyl, COOR 4 , COO-aryl, CO—O-alkoxyalkyl, CONFR 4 , C(NR 4 )N(R 4 ) 2 , C(S)N(R 4 ) 2 , CON(R 4 ) 2 , chloro, bromo, fluoro, iodo, CN, N 3 , OH, OR 4 , NH 2 , NHR 4 , NR 4 R 5 , SH or SR 5 , —C(═S)NH 2 , —C(═NH)NH 2 , —C-(5-membered heterocycle) having one or more O, S or N atoms, —C-imidazole; cycloalkyl, acyl, Br-vinyl, —O-alkyl, O-alkenyl, O-alkynyl, O-aryl, O-aralkyl, —O-acyl, O-cycloalkyl, NH-alkyl, N-dialkyl, NH-acyl, N-aryl, N-aralkyl, NH-cycloalkyl, SH, S-alkyl, S-acyl, S-aryl, S-cycloalkyl, S-aralkyl, CO 2 -alkyl, CONH-alkyl, CON-dialkyl, CF 3 , CH m OH, (CH 2 ) m NH 2 , (CH 2- ) m C(O)OH, (CH 2 ) n CN, (CH 2 ) m NO 2 (CH 2 ) m CONH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 3-6 cycloalkylamino, C 1-4 alkoxycarbonyl, N 3 or C 1-6 alkoxy;
each Y 3 is independently H, F, Cl, Br or I;
each R 4 and R 5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl.
X is O or CH;
each R 6 is independently an optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, —(CH 2 ) m C(O)OR 4 , —(CH 2 ) m C(O)NHR 4 , (CH 2 ) m C(O)N(R 4 ) 2 , C(O)OR 4 or cyano;
each R 7 is independently OH, OR 2 , optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted heteroaryl, —(CH 2 ) m C(O)OR 4 , —(CH 2 ) m C(O)SR 4 —(CH 2 ) m C(O)NHR 4 , (CH 2 ) m C(O)N(R 4 ) 2 , —C(O)OR 4 , —C(O)SR 4 , —O(R 4 ), —S(R 4 ), NO 2 , —NR 4 R 5 , azido, cyano, SCN, OCN, NCO or halo;
each R 8 and R 11 is independently hydrogen, an optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, alkenyl, alkynyl, haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, —CH 2 C(O)N(R 4 ) 2 , —(CH 2 ) m C(O)OR 4 , —(CH 2 ) m C(O)NHR 4 , —C(O)OR 4 , cyano, NH-acyl or N(acyl) 2 ;
each R 9 and R 10 are independently hydrogen, OH, OR 2 , optionally substituted alkyl, CH 3 , CH 2 CN, CH 2 N 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 OH, halogenated alkyl, CF 3 , C(Y 3 ) 3 , 2-Br-ethyl, CH 2 F, CH 2 Cl, CH 2 CF 3 , CF 2 CF 3 , C(Y 3 ) 2 C(Y 3 ) 3 , optionally substituted alkenyl, alkenyl, alkynyl, NO 2 , haloalkenyl, Br-vinyl, optionally substituted alkynyl, haloalkynyl, optionally substituted carbocycle, optionally substituted heterocycle, optionally substituted heteroaryl, —(CH 2 ) m C(O)OR 4 —(CH 2 ) m C(O)SR 4 , —(CH 2 ) m C(O)NHR 4 , —(CH 2 ) m C(O)N(R 4 ) 2 , —C(O)OR 4 , —C(O)SR 4 , —O(R), —O(aralkyl), —S(R 4 ), NO 2 , —NR 4 R 5 , —NH(aralkyl), azido, cyano, SCN, OCN, NCO or halo;
each m is independently 1 or 2; and
alternatively, R 6 and R 10 , R 7 and R 9 , R 8 and R 7 or R 9 and R 11 can come together to form a bridged compound selected from the group consisting of optionally substituted carbocycle or optionally substituted heterocycle; or
alternatively, R 6 and R 7 or R 9 and R 10 can come together to form a spiro compound selected from the group consisting of optionally substituted carbocycle or optionally substituted heterocycle.
11 . The compound of claim 10 wherein X is O.
12 . The compound of claim 10 wherein each R 6 is independently an optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, CH 2 OH, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 F, CH 2 Cl, CH 2 N 3 , CH 2 CN, CH 2 CF 3 , CF 3 , CF 2 CF 3 .
13 . The compound of claim 10 wherein each R 7 is independently —OH, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aralkyl, —O-cycloalkyl-, O-acyl, F, Cl, Br, I, CN, NC, SCN, OCN, NCO, NO 2 , NH 2 , N 3 , NH-acyl, NH-alkyl, N-dialkyl, NH-alkenyl, NH-alkynyl, NH-aralkyl, NH-cycloalkyl, SH, S-alkyl, S-alkenyl, S-alkynyl, S-aralkyl, S-acyl, S-cycloalkyl, CO 2 -alkyl, CONH-alkyl, CON-dialkyl, CONH-alkenyl, CONH-alkynyl, CONH-aralkyl, CONH-cycloalkyl, CH 2 OH, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 F, CH 2 Cl, CH 2 N 3 , CH 2 CN, CH 2 CF 3 , CF 3 , CF 2 CF 3 , (CH 2 ) m COOH, (CH 2 ) m CONH 2 , an optionally substituted 3-7 membered carbocyclic, and an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination.
14 . The compound of claim 10 wherein each R 9 is independently hydrogen, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, —OH, —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aralkyl, —O-cycloalkyl-, O-acyl, F, Cl, Br, I, CN, NC, SCN, OCN, NCO, NO 2 , NH 2 , N 3 , NH-acyl, NH-alkyl, N-dialkyl, NH-alkenyl, NH-alkynyl, NH-aralkyl, NH-cycloalkyl, SH, S-alkyl, S-alkenyl, S-alkynyl, S-aralkyl, S-acyl, S-cycloalkyl, CO 2 -alkyl, CONH-alkyl, CON-dialkyl, CONH-alkenyl, CONH-alkynyl, CONH-aralkyl, CONH-cycloalkyl, CH 2 OH, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 F, CH 2 Cl, CH 2 N 3 , CH 2 CN, CH 2 CF 3 , CF 3 , CF 2 CF 3 , (CH 2 ) m COOH, (CH 2 ) m CONH 2 , an optionally substituted 3-7 membered carbocyclic, and an optionally substituted 3-7 membered heterocyclic ring having O, S and/or N independently as a heteroatom taken alone or in combination.
15 . The compound of claim 10 wherein each R 10 is independently hydrogen, an optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, CH 2 OH, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 N(CH 3 ) 2 , CH 2 F, CH 2 Cl, CH 2 N 3 , CH 2 CN, CH 2 CF 3 , CF 3 , CF 2 CF 3 , (CH 2 ) m COOH, (CH 2 ) m CONH.
16 . The compound of claim 10 wherein each R 8 and R 11 is independently H, CH 3 , CH 2 OH, CH 2 F, CH 2 N 3 , (CH 2 ) m COOH, (CH 2 ) m CONH 2 , and N-acyl.
17 . The compound of claim 10 wherein A is CONH 2 .
18 . The compound of claim 10 wherein each m is independently 1.
19 . A method for the treatment or propylaxis of a host infected with a flavivirus, pestivirus or hepacivirus infection comprising administering to the host an effective treatment amount of a compound of claim 1 , 9 or 10 , optionally in a pharmaceutically acceptable carrier.
20 . The method of claim 19 , wherein the infection is an HCV infection.
21 . The method of claim 19 , wherein the infection is not an HCV infection.
22 . The method of claim 19 wherein the host is at risk of being infected with a flavivirus, pestivirus or hepacivirus.
23 . The method of claim 19 , further comprising administering at least a second antiviral agent.
24 . The method of claim 23 wherein the second antiviral agent is selected from the group consisting of Interferon; Ribavirin; Protease inhibitors (such as Substrate-based NS3 protease inhibitors, Non-substrate-based inhibitors, Phenanthrenequinones possessing activity against protease and Selective NS3 inhibitors); Thiazolidine derivatives; Thiazolidines and benzanilides; Helicase; Polymerase inhibitors; Antisense phosphorothioate oligodeoxynucleotides; Inhibitors of IRES-dependent translation; Nuclease-resistant ribozymes; Nucleoside analogs; 1-amino-alkylcyclohexanes; alkyl lipids; vitamin E and other antioxidants; squalene; amantadine; bile acids; N-(phosphonoacetyl)-L-aspartic acid; benzenedicarboxamides; polyadenylic acid derivatives; 2′,3′-dideoxyinosine; benzimidazoles; plant extracts; and piperidenes.
25 . A pharmaceutical composition for the treatment of a host infected with a flavivirus, pestivirus or hepacivirus infection comprising a treatment effective amount of a compound of claim 1 , 9 or 10 , or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier.
26 . The composition of claim 25 further comprising at least a second antiviral agent.
27 . The composition of claim 26 wherein the second antiviral agent is selected from the group consisting of Interferon; Ribavirin; Protease inhibitors (such as Substrate-based NS3 protease inhibitors, Non-substrate-based inhibitors, Phenanthrenequinones possessing activity against protease and Selective NS3 inhibitors); Thiazolidine derivatives; Thiazolidines and benzanilides; Helicase; Polymerase inhibitors; Antisense phosphorothioate oligodeoxynucleotides; Inhibitors of IRES-dependent translation; Nuclease-resistant ribozymes; Nucleoside analogs; 1-amino-alkylcyclohexanes; alkyl lipids; vitamin E and other antioxidants; squalene; amantadine; bile acids; N-(phosphonoacetyl)-L-aspartic acid; benzenedicarboxamides; polyadenylic acid derivatives; 2′,3′-dideoxyinosine; benzimidazoles; plant extracts; and piperidenes.